Do analysts prefer BPTSY or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, BPTSY or QLGN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A

Is BPTSY or QLGN more profitable?

Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Qualigen Therapeutics N/A N/A -202.16%

Do analysts prefer MEHA or BPTSY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Functional Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, MEHA or BPTSY?

Functional Brands has higher revenue and earnings than Biophytis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Functional Brands $6.61M 0.13 $760K -$0.32 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is MEHA or BPTSY more profitable?

Company Net Margins Return on Equity Return on Assets Functional Brands N/A N/A N/A Biophytis N/A N/A N/A

Do analysts recommend BPTSY or SLXN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, BPTSY or SLXN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Silexion Therapeutics N/A N/A -$11.91M -$80.50 N/A

Is BPTSY or SLXN more profitable?

Biophytis' return on equity of 0.00% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Silexion Therapeutics N/A -516.86% -176.68%

Which has stronger earnings & valuation, ORGS or BPTSY?

Biophytis has lower revenue, but higher earnings than Orgenesis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orgenesis $662K 3.51 -$55.36M -$11.51 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is ORGS or BPTSY more profitable?

Biophytis has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% Biophytis N/A N/A N/A

Do analysts rate UPC or BPTSY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, UPC or BPTSY?

Universe Pharmaceuticals has higher revenue and earnings than Biophytis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Universe Pharmaceuticals $17.86M 0.10 -$3.67M N/A N/A Biophytis N/A N/A -$18.43M N/A N/A

Is UPC or BPTSY more profitable?

Company Net Margins Return on Equity Return on Assets Universe Pharmaceuticals N/A N/A N/A Biophytis N/A N/A N/A

Biophytis (BPTSY) Competitors

$0.25 0.00 (0.00%)

As of 06/12/2026

Compare

BPTSY vs. QLGN, MEHA, SLXN, ORGS, and UPC

Should you buy Biophytis stock or one of its competitors? MarketBeat compares Biophytis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biophytis include Qualigen Therapeutics (QLGN), Functional Brands (MEHA), Silexion Therapeutics (SLXN), Orgenesis (ORGS), and Universe Pharmaceuticals (UPC). These companies are all part of the "pharmaceutical products" industry.

How does Biophytis compare to Qualigen Therapeutics?

Biophytis (NASDAQ:BPTSY) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Biophytis has a beta of 2.46, suggesting that its share price is 146% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 3.7% of Biophytis shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-202.16%

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
Biophytis	Neutral
Qualigen Therapeutics	Neutral

Summary

Biophytis and Qualigen Therapeutics tied by winning 3 of the 6 factors compared between the two stocks.

How does Biophytis compare to Functional Brands?

Functional Brands (NASDAQ:MEHA) and Biophytis (NASDAQ:BPTSY) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Company	Net Margins	Return on Equity	Return on Assets
Functional Brands	N/A	N/A	N/A
Biophytis	N/A	N/A	N/A

In the previous week, Functional Brands had 3 more articles in the media than Biophytis. MarketBeat recorded 3 mentions for Functional Brands and 0 mentions for Biophytis. Functional Brands' average media sentiment score of 0.43 beat Biophytis' score of 0.00 indicating that Functional Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Functional Brands	Neutral
Biophytis	Neutral

Functional Brands has higher revenue and earnings than Biophytis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Functional Brands	$6.61M	0.13	$760K	-$0.32	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

0.1% of Biophytis shares are held by institutional investors. 4.3% of Functional Brands shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Functional Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Functional Brands beats Biophytis on 6 of the 7 factors compared between the two stocks.

How does Biophytis compare to Silexion Therapeutics?

Biophytis (NASDAQ:BPTSY) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

In the previous week, Silexion Therapeutics had 2 more articles in the media than Biophytis. MarketBeat recorded 2 mentions for Silexion Therapeutics and 0 mentions for Biophytis. Silexion Therapeutics' average media sentiment score of 1.92 beat Biophytis' score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biophytis	Neutral
Silexion Therapeutics	Very Positive

Biophytis has a beta of 2.46, suggesting that its stock price is 146% more volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.32, suggesting that its stock price is 132% less volatile than the broader market.

Biophytis' return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Silexion Therapeutics	N/A	-516.86%	-176.68%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A

0.1% of Biophytis shares are held by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are held by institutional investors. 3.7% of Biophytis shares are held by insiders. Comparatively, 5.0% of Silexion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Silexion Therapeutics beats Biophytis on 7 of the 10 factors compared between the two stocks.

How does Biophytis compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Orgenesis has a beta of 2.89, indicating that its stock price is 189% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market.

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by company insiders. Comparatively, 3.7% of Biophytis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
Biophytis	Neutral

Biophytis has lower revenue, but higher earnings than Orgenesis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	3.51	-$55.36M	-$11.51	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Biophytis has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Biophytis	N/A	N/A	N/A

Summary

Biophytis beats Orgenesis on 4 of the 7 factors compared between the two stocks.

How does Biophytis compare to Universe Pharmaceuticals?

Universe Pharmaceuticals (NASDAQ:UPC) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Biophytis	N/A	N/A	N/A

Universe Pharmaceuticals has higher revenue and earnings than Biophytis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	0.10	-$3.67M	N/A	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Comparatively, 3.7% of Biophytis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Universe Pharmaceuticals had 1 more articles in the media than Biophytis. MarketBeat recorded 1 mentions for Universe Pharmaceuticals and 0 mentions for Biophytis. Universe Pharmaceuticals' average media sentiment score of 1.87 beat Biophytis' score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Universe Pharmaceuticals	Very Positive
Biophytis	Neutral

Universe Pharmaceuticals has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, meaning that its stock price is 146% more volatile than the broader market.

Summary

Universe Pharmaceuticals beats Biophytis on 7 of the 8 factors compared between the two stocks.

Get Biophytis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTSY vs. The Competition

Export

Metric	Biophytis	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$586K	$970.92M	$6.50B	$12.37B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	N/A	1.47	24.01	24.71
Price / Sales	N/A	127.72	540.55	165.59
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	-0.02	8.02	10.55	6.85
Net Income	-$18.43M	-$4.88M	$3.56B	$337.45M
7 Day Performance	N/A	4.75%	1.54%	2.70%
1 Month Performance	N/A	4.52%	2.48%	4.60%
1 Year Performance	N/A	47.58%	26.49%	32.81%

Biophytis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30
QLGN Qualigen Therapeutics	N/A	$1.29 +11.2%	N/A	-62.5%	$2.19M	N/A	N/A	50	Gap Up
MEHA Functional Brands	0.4787 of 5 stars	$0.04 -15.2%	N/A	N/A	$2.17M	$6.61M	N/A	33	News Coverage Gap Up
SLXN Silexion Therapeutics	1.1438 of 5 stars	$4.17 -16.4%	N/A	-97.6%	$2.09M	N/A	N/A	N/A	Positive News Gap Up
ORGS Orgenesis	N/A	$0.40 -19.2%	N/A	-74.6%	$2.07M	$662K	N/A	150	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTSY) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biophytis (BPTSY) Competitors

BPTSY vs. QLGN, MEHA, SLXN, ORGS, and UPC

How does Biophytis compare to Qualigen Therapeutics?

Summary

How does Biophytis compare to Functional Brands?

Summary

How does Biophytis compare to Silexion Therapeutics?

Summary

How does Biophytis compare to Orgenesis?

Summary

How does Biophytis compare to Universe Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY vs. The Competition

Biophytis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biophytis (BPTSY) Competitors

BPTSY vs. QLGN, MEHA, SLXN, ORGS, and UPC

How does Biophytis compare to Qualigen Therapeutics?

Which has more risk & volatility, BPTSY or QLGN?

Do analysts prefer BPTSY or QLGN?

Which has higher earnings & valuation, BPTSY or QLGN?

Do institutionals and insiders hold more shares of BPTSY or QLGN?

Is BPTSY or QLGN more profitable?

Does the media favor BPTSY or QLGN?

Summary

How does Biophytis compare to Functional Brands?

Is MEHA or BPTSY more profitable?

Does the media favor MEHA or BPTSY?

Which has higher valuation & earnings, MEHA or BPTSY?

Do institutionals & insiders hold more shares of MEHA or BPTSY?

Do analysts prefer MEHA or BPTSY?

Summary

How does Biophytis compare to Silexion Therapeutics?

Does the media refer more to BPTSY or SLXN?

Which has more volatility and risk, BPTSY or SLXN?

Is BPTSY or SLXN more profitable?

Which has stronger earnings & valuation, BPTSY or SLXN?

Do institutionals and insiders have more ownership in BPTSY or SLXN?

Do analysts recommend BPTSY or SLXN?

Summary

How does Biophytis compare to Orgenesis?

Which has more volatility & risk, ORGS or BPTSY?

Do insiders and institutionals have more ownership in ORGS or BPTSY?

Does the media favor ORGS or BPTSY?

Which has stronger earnings & valuation, ORGS or BPTSY?

Is ORGS or BPTSY more profitable?

Summary

How does Biophytis compare to Universe Pharmaceuticals?

Do analysts rate UPC or BPTSY?

Is UPC or BPTSY more profitable?

Which has stronger earnings and valuation, UPC or BPTSY?

Do institutionals & insiders believe in UPC or BPTSY?

Does the media prefer UPC or BPTSY?

Which has more volatility and risk, UPC or BPTSY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY vs. The Competition

Biophytis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools